Live Breaking News & Updates on Btrastuzumab

Stay updated with breaking news from Btrastuzumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer. ....

Antonio Llombart Cussac , University Hospital Arnau De Vilanova , Oncology Service , Medical Oncology Service , Her2 Positive Early Breast Cancer , Chemotherapy Free Regimen ,

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma. ....

United States , Chrys Kokino , Henlius Trastuzumab , Binish Chudgar , Jason Zhu , European Medicines Agency , National Medical Products Administration , Henlius Biotech Inc , Intas Pharmaceuticals , European Union , European Commission , Henlius Biotech , North America , Accord Biopharma , Trastuzumab Strf , Her2 Overexpressing Breast Cancer , Her2 Overexpressing Metastatic Gastric Or Gej Adenocarcinoma ,

Exploratory Analyses of KATHERINE Trial Inform Adjuvant T-DM1 Use in HER2+ Breast Cancer

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more. ....

United States , Maria Hafez , Sidney Kimmel Medical College , Science Summit , Breast Cancer Clinical Research , Sidney Kimmel Cancer Center , Thomas Jefferson University , Prediction Analysis , Absolute Intrinsic Molecular , Katherine Trial , Her2 Positive Breast Cancer , Breast Cancer , Ado Trastuzumab Emtansine , T Dm1 , Sidney Kimmel Cancer Center , Thomas Jefferson University ,

Subcutaneous Trastuzumab Induces Immune Function in HER2+ Breast Cancer

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer ....

Easter Cooperative Oncology Group , Her2 Breast Cancer , Breast Cancer , Residual Disease ,

Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+ Early Breast Cancer

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial. ....

San Antonio , United States , Neu Isenburg , Centre For Haematology , German Breast Group , Goethe University , Antonio Breast Cancer , Sibylle Loibl , Oncology Bethanien , San Antonio Breast Cancer Symposium , Hr Positive , Er2 Negative Early Stage Breast Cancer , Adjuvantt Dm1 , Ct01772472 ,